Based in Cambridge, UK , Salary – Competitive

In the pharmaceutical industry, there is a clear drive to improve the clinical predictivity of compound screening and profiling assays used in the drug discovery process. High content biology provides a unique means to integrate disease-relevant cell screening early in drug discovery through combining cellular imaging of complex biological systems with the efficiency of high-throughput techniques.

The High Content Biology group, part of Discovery Sciences is a multidisciplinary research unit in R&D working on projects at the heart of contemporary drug discovery. A dynamic research group with a global remit, we develop phenotypic assays and high-content approaches to make significant contributions to projects across the AstraZeneca portfolio. The group is housed in world-class cellular and tissue imaging facilities and works to impact on multiple areas of drug discovery; interrogating novel biology (e.g. stem cell biology) through phenotypic screening, providing early insight into compound toxicity and characterizing compound mode of action in disease relevant models.

We are seeking talented, highly motivated bioscientists to develop and implement complex in vitro models and high-content assay approaches with physiological relevance across multiple therapy areas. The successful candidates will become integral members of early drug discovery projects at AstraZeneca, engaging with external collaborators where appropriate. You will have opportunities to help shape the necessary high-content infrastructure for our projects as well as identifying, validating and implementing innovative solutions to advance drug discovery.

For more information :

Reference Number:RD1200